John A Orwin Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for John A Orwin.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of John A Orwin. John A Orwin is in ARRAY BIOPHARMA INC ($ARRY) and Director in ARRAY BIOPHARMA INC ($ARRY) and Director in SEATTLE GENETICS INC /WA ($SGEN) and Director in NeurogesX Inc ($NGSX) and President & CEO in Relypsa Inc ($RLYP) and Director in Retrophin, Inc. ($RTRX) and President & CEO in Atreca, Inc. ($BCEL).
Latest Insider Trading Transactions of John A Orwin
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ARRY, BCEL, NGSX, RLYP, SGEN, RTRX
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 29 2021 | BCEL | Atreca, Inc. | Orwin John A | President & CEO | Option Exercise | A | 13.97 | 260,000 | 3,632,200 | 260,000 | |
| May 19 2020 | RTRX | Retrophin, Inc. | Orwin John A | Director | Option Exercise | A | 15.43 | 9,000 | 138,870 | 9,000 | |
| May 19 2020 | RTRX | Retrophin, Inc. | Orwin John A | Director | Grant | A | 0.00 | 3,000 | 0 | 11,875 | 8.9 K to 11.9 K (+33.80 %) |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | Orwin John A | Director | Option Exercise | A | 160.33 | 3,171 | 508,406 | 3,171 | |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | Orwin John A | Director | Grant | A | 0.00 | 1,335 | 0 | 26,098 | 24.8 K to 26.1 K (+5.39 %) |
| Mar 19 2020 | BCEL | Atreca, Inc. | Orwin John A | President & CEO | Buy | P | 12.79 | 6,000 | 76,740 | 6,000 | 0 to 6 K |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Director | Option Exercise | D | 14.55 | 25,000 | 363,750 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Director | Option Exercise | D | 10.47 | 25,000 | 261,750 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Director | Option Exercise | D | 5.95 | 25,000 | 148,750 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Director | Option Exercise | D | 5.13 | 25,000 | 128,250 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Director | Option Exercise | D | 3.87 | 25,000 | 96,750 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Director | Option Exercise | D | 5.60 | 25,000 | 140,000 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Director | Option Exercise | D | 4.51 | 20,000 | 90,200 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Director | Sell | D | 0.00 | 5,000 | 0 | 0 | 5 K to 0 (-100.00 %) |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Director | Sell | D | 48.00 | 15,000 | 720,000 | 5,000 | 20 K to 5 K (-75.00 %) |
| May 22 2019 | SGEN | SEATTLE GENETICS I ... | Orwin John A | Director | Option Exercise | A | 64.38 | 7,038 | 453,106 | 7,038 | |
| May 22 2019 | SGEN | SEATTLE GENETICS I ... | Orwin John A | Director | Grant | A | 0.00 | 2,963 | 0 | 24,763 | 21.8 K to 24.8 K (+13.59 %) |
| May 22 2019 | SGEN | SEATTLE GENETICS I ... | Orwin John A | Director | Option Exercise | A | 64.38 | 7,038 | 453,106 | 7,038 | |
| May 22 2019 | SGEN | SEATTLE GENETICS I ... | Orwin John A | Director | Grant | A | 0.00 | 2,963 | 0 | 24,763 | 21.8 K to 24.8 K (+13.59 %) |
| May 10 2019 | RTRX | Retrophin, Inc. | Orwin John A | Director | Option Exercise | A | 17.94 | 8,000 | 143,520 | 8,000 | |
| May 10 2019 | RTRX | Retrophin, Inc. | Orwin John A | Director | Grant | A | 0.00 | 2,000 | 0 | 8,875 | 6.9 K to 8.9 K (+29.09 %) |
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | A | 0.00 | 25,000 | 0 | 25,000 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Buy | M | 0.00 | 5,000 | 0 | 15,000 | 10 K to 15 K (+50.00 %) | |
| May 22 2018 | SGEN | SEATTLE GENETICS I ... | Orwin John A | Director | Option Exercise | A | 56.77 | 9,260 | 525,690 | 9,260 | |
| May 22 2018 | SGEN | SEATTLE GENETICS I ... | Orwin John A | Director | Grant | A | 0.00 | 3,700 | 0 | 21,800 | 18.1 K to 21.8 K (+20.44 %) |
| May 11 2018 | RTRX | Retrophin, Inc. | Orwin John A | Director | Option Exercise | A | 26.52 | 10,000 | 265,200 | 10,000 | |
| May 11 2018 | RTRX | Retrophin, Inc. | Orwin John A | Director | Grant | A | 0.00 | 2,500 | 0 | 6,875 | 4.4 K to 6.9 K (+57.14 %) |
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | A | 10.47 | 25,000 | 261,750 | 25,000 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Buy | M | 10.47 | 5,000 | 52,350 | 10,000 | 5 K to 10 K (+100.00 %) | |
| May 23 2017 | SGEN | SEATTLE GENETICS I ... | Orwin John A | Director | Option Exercise | A | 66.60 | 9,260 | 616,716 | 9,260 | |
| May 23 2017 | SGEN | SEATTLE GENETICS I ... | Orwin John A | Director | Grant | A | 0.00 | 3,700 | 0 | 18,100 | 14.4 K to 18.1 K (+25.69 %) |
| Mar 27 2017 | RTRX | Retrophin, Inc. | Orwin John A | Director | Option Exercise | A | 17.53 | 17,500 | 306,775 | 17,500 | |
| Mar 27 2017 | RTRX | Retrophin, Inc. | Orwin John A | Director | Grant | A | 0.00 | 4,375 | 0 | 4,375 | 0 to 4.4 K |
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | A | 5.95 | 25,000 | 148,750 | 25,000 | ||
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Buy | M | 5.83 | 5,000 | 29,150 | 5,000 | 0 to 5 K | |
| Sep 02 2016 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Option Exercise | D | 28.38 | 105,000 | 2,979,900 | 0 | |
| Sep 02 2016 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Option Exercise | D | 27.21 | 94,500 | 2,571,345 | 0 | |
| Sep 02 2016 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Option Exercise | D | 7.40 | 727,877 | 5,386,290 | 0 | |
| Sep 02 2016 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Option Exercise | D | 18.87 | 67,500 | 1,273,725 | 0 | |
| Sep 02 2016 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Option Exercise | A | 18.87 | 45,000 | 849,150 | 67,500 | |
| Sep 02 2016 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Sell | D | 32.00 | 55,000 | 1,760,000 | 0 | 55 K to 0 (-100.00 %) |
| Sep 02 2016 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Sell | U | 32.00 | 10,142 | 324,544 | 55,000 | 65.1 K to 55 K (-15.57 %) |
| Sep 02 2016 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Grant | A | 0.00 | 11,250 | 0 | 65,142 | 53.9 K to 65.1 K (+20.88 %) |
| Aug 17 2016 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Payment of Exercise | F | 31.89 | 3,994 | 127,369 | 53,892 | 57.9 K to 53.9 K (-6.90 %) |
| Jun 07 2016 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Option Exercise | A | 18.87 | 22,500 | 424,575 | 22,500 | |
| Jun 07 2016 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Payment of Exercise | F | 19.96 | 2,114 | 42,195 | 57,886 | 60 K to 57.9 K (-3.52 %) |
| Jun 07 2016 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Grant | A | 0.00 | 5,625 | 0 | 60,000 | 54.4 K to 60 K (+10.34 %) |
| May 24 2016 | SGEN | SEATTLE GENETICS I ... | Orwin John A | Director | Option Exercise | A | 38.82 | 9,260 | 359,473 | 9,260 | |
| May 24 2016 | SGEN | SEATTLE GENETICS I ... | Orwin John A | Director | Grant | A | 0.00 | 3,700 | 0 | 14,400 | 10.7 K to 14.4 K (+34.58 %) |
| Feb 17 2016 | SGEN | SEATTLE GENETICS I ... | Orwin John A | Director | Buy | P | 28.33 | 2,000 | 56,660 | 10,700 | 8.7 K to 10.7 K (+22.99 %) |
| Dec 09 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Option Exercise | M | 7.40 | 10,000 | 74,000 | 727,877 | |
| Dec 09 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Sell | S | 29.67 | 800 | 23,733 | 54,375 | 55.2 K to 54.4 K (-1.45 %) |
| Dec 09 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Sell | S | 28.52 | 7,379 | 210,451 | 55,175 | 62.6 K to 55.2 K (-11.80 %) |
| Dec 09 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Sell | S | 27.85 | 6,821 | 189,949 | 62,554 | 69.4 K to 62.6 K (-9.83 %) |
| Dec 09 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Buy | M | 7.40 | 10,000 | 74,000 | 69,375 | 59.4 K to 69.4 K (+16.84 %) |
| Dec 04 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Option Exercise | M | 7.40 | 20,000 | 148,000 | 737,877 | |
| Dec 04 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Option Exercise | M | 7.40 | 20,000 | 148,000 | 757,877 | |
| Dec 04 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Sell | S | 25.00 | 20,000 | 500,000 | 59,375 | 79.4 K to 59.4 K (-25.20 %) |
| Dec 04 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Buy | M | 7.40 | 20,000 | 148,000 | 79,375 | 59.4 K to 79.4 K (+33.68 %) |
| Dec 04 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Sell | S | 25.00 | 20,000 | 500,000 | 59,375 | 79.4 K to 59.4 K (-25.20 %) |
| Dec 04 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Buy | M | 7.40 | 20,000 | 148,000 | 79,375 | 59.4 K to 79.4 K (+33.68 %) |
| Nov 10 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Grant | A | 0.00 | 16,875 | 0 | 59,375 | 42.5 K to 59.4 K (+39.71 %) |
| Nov 02 2015 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | A | 5.13 | 25,000 | 128,250 | 25,000 | ||
| Nov 02 2015 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Aug 19 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Sell | S | 25.00 | 2,366 | 59,150 | 42,500 | 44.9 K to 42.5 K (-5.27 %) |
| Aug 19 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Sell | S | 24.69 | 2,634 | 65,033 | 44,866 | 47.5 K to 44.9 K (-5.55 %) |
| Aug 12 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Option Exercise | A | 28.38 | 105,000 | 2,979,900 | 105,000 | |
| Aug 12 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Grant | A | 0.00 | 22,500 | 0 | 47,500 | 25 K to 47.5 K (+90.00 %) |
| Aug 03 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Option Exercise | M | 7.40 | 5,000 | 37,000 | 777,877 | |
| Aug 03 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Option Exercise | M | 7.40 | 20,000 | 148,000 | 782,877 | |
| Aug 03 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Sell | S | 34.14 | 200 | 6,828 | 25,000 | 25.2 K to 25 K (-0.79 %) |
| Aug 03 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Sell | S | 33.51 | 9,800 | 328,397 | 25,200 | 35 K to 25.2 K (-28.00 %) |
| Aug 03 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Buy | M | 7.40 | 5,000 | 37,000 | 35,000 | 30 K to 35 K (+16.67 %) |
| Aug 03 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Sell | S | 34.11 | 200 | 6,822 | 30,000 | 30.2 K to 30 K (-0.66 %) |
| Aug 03 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Sell | S | 33.57 | 19,800 | 664,751 | 30,200 | 50 K to 30.2 K (-39.60 %) |
| Aug 03 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Buy | M | 7.40 | 20,000 | 148,000 | 50,000 | 30 K to 50 K (+66.67 %) |
| Jun 02 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Option Exercise | M | 7.40 | 8,555 | 63,307 | 802,877 | |
| Jun 02 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Option Exercise | M | 7.40 | 20,000 | 148,000 | 811,432 | |
| Jun 02 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Sell | S | 36.94 | 5,204 | 192,255 | 30,000 | 35.2 K to 30 K (-14.78 %) |
| Jun 02 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Sell | S | 35.79 | 8,351 | 298,893 | 35,204 | 43.6 K to 35.2 K (-19.17 %) |
| Jun 02 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Buy | M | 7.40 | 8,555 | 63,307 | 43,555 | 35 K to 43.6 K (+24.44 %) |
| Jun 02 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Sell | S | 36.98 | 5,306 | 196,208 | 35,000 | 40.3 K to 35 K (-13.16 %) |
| Jun 02 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Sell | S | 36.40 | 14,694 | 534,793 | 40,306 | 55 K to 40.3 K (-26.72 %) |
| Jun 02 2015 | RLYP | Relypsa Inc | Orwin John A | President & CEO | Buy | M | 7.40 | 20,000 | 148,000 | 55,000 | 35 K to 55 K (+57.14 %) |
| May 19 2015 | SGEN | SEATTLE GENETICS I ... | Orwin John A | Director | Option Exercise | A | 39.94 | 9,260 | 369,844 | 9,260 | |
| May 19 2015 | SGEN | SEATTLE GENETICS I ... | Orwin John A | Director | Grant | A | 0.00 | 3,700 | 0 | 8,700 | 5 K to 8.7 K (+74.00 %) |
| Jun 11 2012 | NGSX | NeurogesX Inc | Orwin John A | Director | Option Exercise | A | 0.33 | 10,000 | 3,300 | 10,000 | |
| Feb 09 2012 | NGSX | NeurogesX Inc | Orwin John A | Director | Option Exercise | A | 0.88 | 50,000 | 44,000 | 50,000 | |
| Jun 06 2011 | NGSX | NeurogesX Inc | Orwin John A | Director | Option Exercise | A | 2.35 | 10,000 | 23,500 | 10,000 | |
| Jun 04 2010 | NGSX | NeurogesX Inc | Orwin John A | Director | Option Exercise | A | 7.79 | 10,000 | 77,900 | 10,000 | |
| Nov 23 2009 | NGSX | NeurogesX Inc | Orwin John A | Director | Option Exercise | A | 8.38 | 20,000 | 167,600 | 20,000 |
Page: 1